Improved prediction of the risk of early major bleeding in pulmonary embolism (PE) is needed to optimize acute management.
Does a simple scoring system predict early major bleeding in acute PE patients, identifying patients with either high or low probability of early major bleeding?
From a multicenter prospective registry including 2,754 patients, we performed post hoc multivariable logistic regression analysis to build a risk score to predict early (up to hospital discharge) major bleeding events. We validated the endpoint model internally, using bootstrapping in the derivation dataset by sampling with replacement for 500 iterations. Performances of this novel score were compared with that of the VTE-BLEED, RIETE, and BACS models.
Multivariable regression identified three predictors for the occurrence of 82 major bleeds (3.0%; 95%CI, 2.39%-3.72%) Syncope (+1.5); Anemia, defined as hemoglobin&lt;12 g/dL (+2.5); and Renal Dysfunction, defined as glomerular filtration rate&lt;60mL/min (+1 point) (SARD)-friendly score to estimate risk of early major bleeding in patients with acute PE.Previous studies reported a strong association between sleepiness-related symptoms and comorbidities with poor cardiovascular outcomes among patients with moderate to severe OSA (msOSA). However, the validation of these associations in the Hispanic population from South America and the ability to predict incident cardiovascular disease remain unclear.
In Hispanic patients with msOSA, are four different cluster analyses reproducible and able to predict incident cardiovascular mortality?
Using the SantOSA cohort, we reproduced four cluster analyses (Sleep Heart Health Study [SHHS], Icelandic Sleep Apnea Cohort [ISAC], Sleep Apnea Cardiovascular Endpoints [SAVE], and The Institute de Recherche en Sante Respiratoire des Pays de la Loire [IRSR] cohorts) following a cluster analysis similar to each training dataset. The incidence of cardiovascular mortality was constructed using a Kaplan-Meier (log-rank) model, and Cox proportional hazards models were adjusted by confounders.
Among 780 patients with msOSA iA, a symptom-based approach can validate different OSA patient subtypes, and those with excessive sleepiness have an increased risk of incident cardiovascular mortality in the Hispanic population from South America.Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease associated with significant morbidity and mortality. Nintedanib and pirfenidone are two antifibrotic medications currently approved for slowing the rate of lung function decline in IPF, but information on treatment effect on mortality and risk of acute exacerbation (AE) remains limited or unknown.
Does antifibrotic treatment decrease risk of mortality and AE?
A comprehensive search of several databases, including Ovid MEDLINE(R), Ovid Embase, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus, was conducted. Studies were included if they were original articles comparing mortality or AE events in IPF patients with and without antifibrotic treatment. Relative risk (RR) with 95% confident interval (CI) was pooled using random-effects meta-analyses with inverse variance method, assessing two primary outcomes of all-cause mortality and acute exacerbation (AE) risater heterogeneity with pooled analysis, its effect was robust in subgroup analyses by study type, duration of follow-up, and antifibrotic subtype.A mean pulmonary artery pressure &gt;20mmHg now defines pulmonary hypertension. We hypothesize that echocardiographic thresholds must be adjusted.
Should tricuspid regurgitation velocity thresholds to screen for pulmonary hypertension be revised, given the new hemodynamic definition?
This multicenter retrospective study included 1,608 patients who underwent both echocardiography and right heart catherization within 4weeks. The discovery cohort consisted of 1,081 individuals; the validation cohort included 527. Screening criteria for pulmonary hypertension were derived with the use of receiver operating characteristic analysis and the Youden index, assuming equal cost for false-positive and -negative classification. A lower threshold was calculated with the use of a predefined sensitivity 95%.
In the discovery cohort, echocardiographic tricuspid regurgitation velocity had a good discrimination for pulmonary hypertension area under the curve, 88.4 (95%CI, 85.3-91.5). A 3.4-m/s threshold provided a 78%sensitivity, 87%specificity, and 6.13 positive likelihood ratio to detect pulmonary hypertension; 2.7m/s had a 95%sensitivity and 0.12 negative likelihood ratio to exclude pulmonary hypertension. In the validation cohort, the discovery threshold of 2.7m/s provided sensitivity and negative likelihood ratios of 80%and 0.34, respectively. Right cardiac size improved detection of pulmonary hypertension in the lower tricuspid regurgitation velocity groups.
Our data support a lower tricuspid regurgitation velocity of approximately 2.7m/s for screening pulmonary hypertension, with a high sensitivity in tertiary referral centers. https://www.selleckchem.com/PI3K.html Right heart chamber measurements improve the diagnostic yield of echocardiography.
Our data support a lower tricuspid regurgitation velocity of approximately 2.7 m/s for screening pulmonary hypertension, with a high sensitivity in tertiary referral centers. Right heart chamber measurements improve the diagnostic yield of echocardiography.Reduced physical activity is common in COPD and is associated with poor outcomes. Physical activity is therefore a worthy target for intervention in clinical trials; however, trials evaluating physical activity have used heterogeneous methods.
What is the available evidence on the efficacy and/or effectiveness of various interventions to enhance objectively measured physical activity in patients with COPD, taking into account the minimal preferred methodologic quality of physical activity assessment?
In this narrative review, the COPD Biomarker Qualification Consortium (CBQC) task force searched three scientific databases for articles that reported the effect of an intervention on objectively measured physical activity in COPD. Based on scientific literature and expert consensus, only studies with? 7 measurement days and? 4 valid days of? 8h of monitoring were included in the primary analysis.
Thirty-seven of 110 (34%) identified studies fulfilled the criteria, investigating the efficacy and/or effectiveness of physical activity behavior change programs (n= 7), mobile or electronic-health interventions (n= 9), rehabilitative exercise (n= 9), bronchodilation (n= 6), lung volume reduction procedures (n= 3), and other interventions (n= 3).